Loading...
•
Sep 30, 2021
Quanterix Q3 2021 Earnings Report
Announced third quarter financial results, highlighting growth in consumables and instruments.
Key Takeaways
Quanterix reported strong third-quarter results driven by significant growth in consumables and instruments. The company is making progress in neurology and infectious disease with recent FDA designations.
Third quarter revenue driven by unprecedented growth in consumables (+98% vs PY) and instruments (+44% vs PY)
Simoa phospho-Tau 181 (pTau-181) blood test is a critical potential aid in the diagnostic evaluation of Alzheimer’s disease
Expanded EUA label for a COVID-19 test by the U.S. FDA
Simoa SARS-CoV-2 N Protein Antigen Test demonstrates potential for achieving asymptomatic and low-invasive clinical testing
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...